Clear

Search Results Within Category "Prevention"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
3results

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

clinicaltrials@northshore.org

ALL
18 years to 75 years old
PHASE2
This study is NOT accepting healthy volunteers
NCT06143956
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Have a body mass index (BMI) * ≥30 kilogram/square meter (kg/m²), or * ≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity * Have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss.
Exclusion Criteria:
* Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure. * Have a history of symptomatic gallbladder disease within the past 2 years. * Have a lifetime history of suicide attempts.
DRUG: LY3305677, DRUG: LY3841136, DRUG: Tirzepatide, DRUG: Placebo, DRUG: LY3549492
Obesity, Overweight
I'm interested

Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss (LIGHT)

clinicaltrials@northshore.org

ALL
18 years and over
This study is NOT accepting healthy volunteers
NCT06894498
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Subject is ≥ 18 years of age at the time of the ESG procedure * Subject with a BMI between 30 kg/m2 and 50 kg/m2, inclusive, at the time of the primary ESG procedure using Overstitch Endoscopic Suturing System * Subject completed follow-up 1-year from the ESG procedure for weight loss management * Subject completed or is eligible for follow-up 5-years from the ESG procedure for weight loss management (visit can be collected either retrospectively or prospectively) * Subject has returned for a minimum of one annual follow-up at the treating site for weight loss management annually between two and four years from the procedure. * Subject is willing to complete one prospective visit (5 year or 5+ year, as appropriate) * Subject is able to read, understand, and sign a written Informed Consent Form to participate in the study
Exclusion Criteria:
* None
OTHER: No Intervention: Observational Cohort
Obesity and Obesity-related Medical Conditions, Weight Loss
I'm interested

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2)

clinicaltrials@northshore.org

ALL
18 years and over
PHASE3
This study is NOT accepting healthy volunteers
NCT07282600
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Have type 2 diabetes * Are on stable treatment for type 2 diabetes for at least 90 days prior to screening * Have a BMI ≥ 27 kg/m2 * Have a stable body weight (\<5% body weight change) for 90 days prior to screening
Exclusion Criteria:
* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes * Have taken any of the following antihyperglycemic medications within 90 days before screening: * amylin analogs * glucagon-like peptide-1 (GLP-1) receptor agonists * glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or * insulin * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening
DRUG: Eloralintide, DRUG: Placebo
Overweight, Obesity
Type 2 Diabetes
I'm interested